Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Tempting to throw the baby out with the bath water

DGL Group
3:27pm
February 27, 2024
DGL delivered a weak 1H24, with NPAT declining 41% on the pcp, well below both our expectations and consensus. Whilst an element of the performance is cyclical, company guidance sees only modest improvement in 2H24, with the company forecasting FY24 NPAT to decline on the pcp. In discussing the result, management talked about investing for growth, expensing costs where possible, to allow the company to grow organically in years to come – something that comes at the cost of current P&L earnings. Whilst the narrative resonates, it isn’t lost on us that the predictability of DGL’s earnings continues to decline – DGL is likely to grow slower than we expected, with earnings more cyclical. It is on this basis that we apply a lower multiple to lower earnings, whilst retaining our Add recommendation on a lower target price of $0.77/sh.

Managing softer conditions well

Reece
3:27pm
February 27, 2024
REH’s 1H24 result was above expectations with earnings growth delivered in both ANZ and the US despite subdued macroeconomic conditions. Key positives: Group EBITDA margin increased 60bp to 11.6% with margins higher in both regions; ROCE rose 80bp to 16.1%; Balance sheet remains healthy with ND/EBITDA falling to 0.7x (FY23: 0.9x). Key negative: Demand remains subdued with management expecting a softening environment in ANZ in 2H24. We increase FY24-26F EBITDA by between 10-12%. Our target price increases to $22.10 (from $15.50) on the back of updates to earnings forecasts and a roll-forward of our model to FY25 forecasts. With a 12-month forecast TSR of -22%, we retain our Reduce rating. We continue to see REH as a good business with a strong brand and a long-term track record of investment for growth. However, trading on 41.9x FY25F PE and 1.0% yield, we think the stock is overvalued in the short term, especially relative to our growth forecast (3-year EPS CAGR of 5%).

Supermarkets performing well

Coles Group
3:27pm
February 27, 2024
COL’s 1H24 results was above expectations driven mainly by the core Supermarkets segment. Key positives: Supermarkets Own Brand sales increased 7.6% with eCom sales jumping 29.2%; Investments to reduce total loss saw an improvement in loss through 2Q24 with expectations for further benefits in 2H24; Supermarkets sales growth of 4.9% in early 2H24 was well above Woolworths’ (WOW) Australian Food growth of ~1.5%. Key negatives: Liquor earnings were below our forecast; Group EBIT margin fell 30bp to 4.8%. Following the better-than-expected 1H24 result and solid start to 2H24, we increase FY24-26F underlying EBIT by between 3-4%. This reflects upgrades to Supermarkets earnings forecasts, partially offset by downgrades to Liquor. Our target price rises by $18.70 (from $16.60) on the back of updates to earnings forecasts and a roll-forward of our model to FY25 forecasts. We maintain our Add rating with COL being our preference in the Consumer Staples sector.

Topline headwinds remain but margins improving

Articore
3:27pm
February 27, 2024
Articore Group’s (ATG) 1H24 marketplace revenue (MPR) was ~5% under consensus at ~A$260m (-13% on pcp on a constant currency basis) but broadly in line with consensus at GPAPA (~A$64m, +19% on pcp). Whilst management initiatives around improving the margin profile of the business appear on track, we note ATG expects the softer consumer environment to persist into the 2H and hence topline growth eludes at this juncture. We make several adjustments to our medium-term forecasts, predominantly related to: 1) the lower marketplace revenue environment; and 2) the narrowed FY24 margin guidance (details below). Our price target is altered marginally to A$0.70 from (A$0.71). Hold maintained.

1H in line- Working on a “step-change” in core ops

Healius
3:27pm
February 27, 2024
1H results were pre-released so in line, with underlying Op income falling by double-digits and margins compressing. Pathology was the main drag, negatively impacted by cycling out of covid-19 testing, combined with low volumes and cost inflation, while Lumus Imaging was “ahead of target” on strength in the hospital and community segments, and Agilex showed “positive signs” on increasing new contracts. While management is accelerating Pathology restructuring to better match volumes with costs, aiming for a “step-change” by FY26/27, uncertainty around the impact of numerous initiatives make forecasting challenging and unreliable. We lower our FY24-26 estimates, with our target price decreasing to A$1.32. Hold

Execution on point

SiteMinder
3:27pm
February 27, 2024
1H24 underlying EBITDA/NPAT was below MorgansF and consensus. Subscribers, revenue, and cashflow were pre-released at SDR’s 2Q24 update. The highlight for us was SDR continuing to demonstrate ongoing improvement in its profitability and unit economics whilst maintaining solid growth momentum. Management said the 2H24 has started well and reiterated FY24 guidance for positive underlying EBITDA and FCF in 2H24. SDR continues to target medium-term organic revenue growth of 30%. We continue to think SDR offers an attractive long-term growth opportunity underpinned by its global underpenetrated TAM and opportunity to better monetise its A$70bn of Gross Booking Value (currently captures ~0.2%). ADD maintained.

Growing across all regions

Polynovo
3:27pm
February 27, 2024
PNV posted its 1H24 results which was in line with our forecasts. Sales momentum across all regions is continuing and we have upgraded our sales forecasts which sees average growth of 32% pa over the next three years. As a result of upgrades to forecasts our TP has increased to A$2.22, and with >10% upside to the target we upgrade our recommendation to Add (from Hold).

Improving profitability but some top-line headwinds

Tyro Payments
3:27pm
February 27, 2024
TYR’s 1H24 normalised gross profit (A$105m) was +~11% on the pcp and in-line with consensus (A$105m), whilst the 1H24 normalised EBITDA (A$27m, +41% on the pcp) was slightly below consensus (-3%).  While 1H24 showed good overall profitability trends, in our view, some issues with the Bendigo Alliance and a tougher core business transaction environment point to a softer top-line outlook in 2H24. We reduce our TYR FY24F/FY25F EBITDA figures by -6%-12% mainly on lower transaction value forecasts. While our EPS estimates in FY24F rise on lower share-based payments, FY25F EPS declines by -13%. Our PT is set at A$1.47 (previously A$1.61). We see recent improvements in TYR’s underlying operating performance as encouraging, and think there remains long-term value in the name. ADD.

1H24 result: Not flying yet, but the bags are packed

Aerometrex
3:27pm
February 27, 2024
AMX has released its 1H report in-line with our expectations. Key focus remains on Annual Recurring Revenue (ARR) growth and cost controls, both improving over the last 12 months. LiDAR growth continues to grab the headlines, but we’re getting the sense MetroMap is back on track with the worst now behind it following a number of years contending with competitive pressures and aviation constraints. We retain an Add recommendation on AMX and continue to see an attractive risk/reward profile with clearer skies ahead. Our valuation and target price increases marginally to A$0.50 p/s (from A$0.45 p/s).

A reboot and ready to fly

ImpediMed
3:27pm
February 27, 2024
IPD released its 1H24 results which were in line with expectations. The new CEO and CFO have set out a clear plan to focus on high volume US states (targeting 11 states by April) and cost control (reduction 10% to 15%). The market will appreciate this clarity. We have made no changes to forecasts, target price or recommendation.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more